The April 4th NEJM publishes results of phase III SWOG-9346, which found that taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuous androgen-deprivation therapy.
Gastric cancer, the number two cancer killer globally, often develops as a result of infection with the bacterium Helicobacter pylori, holding out the promise that campaigns to eradicate the bug in high-risk populations could have a significant public health impact. The SWOG S0701 clinical trial, which spanned six Latin American countries, suggests H. pylori eradication campaigns to prevent gastric cancer would need to be narrowly tailored to subpopulations.
Four of the most promising early career researchers in oncology have been accepted to the 2012 SWOG Young Investigator Training Course, to be held September 10 – 12 in Seattle. This intensive three-day workshop gives early career cancer researchers tools to design and lead large-scale studies across the NCI National Clinical Trials Network.
Left to right:
Christopher Lieu, M.D., Assistant Professor, University of Colorado Cancer Center
William Lowrance, M.D., M.P.H., Assistant Professor, University of Utah Huntsman Cancer Institute
Jatin Shah, M.D., Assistant Professor, MD Anderson Cancer Center
William Nassib William, Jr., M.D., Assistant Professor, MD Anderson Cancer Center
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to women treated with a standard therapy of anastrozole alone (47.7 months vs 41.3 months).
"The combination offers a new standard for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer," says lead study coordinator Rita Mehta, M.D., of the University of California, Irvine Medical Center.
Cancer patients with annual household incomes below $50,000
were less likely to participate in clinical trials than patients with annual incomes of
$50,000 or higher, and were more likely to be concerned about how to pay for
clinical trial participation. This is the conclusion of a large SWOG study presented at the ASCO 2012 meeting by Joseph M. Unger, M.S., Ph.C., of the SWOG Statistical Center and the Fred Hutchinson Cancer Research Center.
The study surveyed 5,499 patients
who registered with an online treatment decision tool.
In the end, 7.6 percent of survey takers with an annual income below $50,000
reported participating in clinical trials, while 10.0 percent of those with incomes of
$50,000 or more said they took part.
Many men with metastatic, hormone‐sensitive prostate cancer live
longer on continuous androgen‐deprivation therapy
than on intermittent therapy, according to results of phase III clinical trial SWOG‐9346, the largest
such study to date in men with metastatic, hormone‐sensitive disease.
The study’s principal investigator,
Maha Hussain, M.D., F.A.C.P., of the University of Michigan Comprehensive Cancer
Center, presented the results at the plenary session of the ASCO 2012 meeting in Chicago.
“Based on these results,” Hussain says, “we can conclude that intermittent AD is not as
effective as continuous AD in men with metastatic prostate cancer.”